Skip to content
Menu

B. Riley Securities Reiterates Buy on PDS Biotechnology, Raises Price Target to $4

Benzinga Newsdesk 3 weeks ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.

B. Riley Securities analyst Mayank Mamtani reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $3 to $4.

Read at benzinga.com

← All stock news